PepScribe Review

What PepScribe charges

• Sermorelin: $99/mo — from; the product page and its FAQ both print the same figure
• Glutathione: $79/mo — from
• NAD+: $129/mo — from
• GHK-Cu: $99/mo — from; a topical cream, not an injection
• Semaglutide: $69/mo — from; the oral form, which the card says has no injections
• Tirzepatide: $109/mo — from; the oral form, which the card says has no injections

Six compounds, six prices

Sermorelin, NAD+, glutathione, a topical copper tripeptide cream and the oral forms of both weight-loss molecules each carry their own starting figure.

The catalogue is easy to misread, because every card renders as a category, a name, a description, the figure, and then the next product's category label — so the number sits between one product and the next.

Walking the page in document order rather than from a deduplicated list changes which product gets which number, which is why the order was checked before anything was filed.

The sermorelin figure is the one that licenses the rest

Sermorelin is the only compound here with a second page of its own, and that page prints a starting figure in its headline and repeats it in its FAQ.

Both agree with what the catalogue card gives when the cards are read in document order.

That agreement is the evidence for the reading order used on the cards that have no second page, and it is the only independent check available on this site.

It names a pharmacy class, not a pharmacy

Its own words on legal category are that its products are "Compounded in the USA by licensed 503A pharmacies. No hidden overseas supply chain", and that "a US-licensed clinician is the prescriber of record".

The only entity it names is a telehealth provider — "Telehealth services are provided by Ola Digital Health, an independent US-licensed telehealth provider" — which is a clinician network rather than a dispenser.

On the dispenser it says only "one of our US-licensed 503A partner pharmacies" compounding under sterile-compounding standards, and that "the exact pharmacy depends on your state". That describes without naming.

No coverage claim at all

The pages read carry no state count, no state list and no fifty of any kind.

So a reader outside a common market has nothing to check before starting an intake.

It also publishes no certificate of analysis. Its sterile-compounding standards are a description of how a pharmacy is meant to work, not a document about the vial that arrives.

How we verified this

• Walked the catalogue in document order rather than from a deduplicated list, because each card prints its figure between one product's description and the next product's category label.
• Confirmed the sermorelin figure a second way on its own product page and in that page's FAQ, and used that agreement to license the reading order for the cards with no second page.
• Read its dispensing sentences in full and recorded a pharmacy class rather than a pharmacy name, since the only named entity is its clinician network.
• Requested a deliberately meaningless address on this host in the same session and confirmed it returns a not-found response.
• Screened the brand against the live federal warning-letter table through a matcher that normalises both the query and the filed company name before comparing, pulling all 3,677 records in pages and filtering locally because the table's own search parameter is ignored, with a positive and a nonsense control in the same run.